Maravai Lifesciences Ownership
| MRVI Stock | USD 5.22 0.26 5.24% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 135.8 M | Current Value 141.6 M | Avarage Shares Outstanding 139.4 M | Quarterly Volatility 53.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Maravai |
Maravai Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of Maravai Lifesciences was now reported as 2.44. The company recorded a loss per share of 1.67. Maravai Lifesciences had not issued any dividends in recent years. Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California. Maravai LifeSciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 470 people. To find out more about Maravai Lifesciences Holdings contact the company at 858 546 0004 or learn more at https://www.maravai.com.Besides selling stocks to institutional investors, Maravai Lifesciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Maravai Lifesciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Maravai Lifesciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Maravai Lifesciences Quarterly Liabilities And Stockholders Equity |
|
Maravai Lifesciences Insider Trades History
Only 1.3% of Maravai Lifesciences Holdings are currently held by insiders. Unlike Maravai Lifesciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Maravai Lifesciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Maravai Lifesciences' insider trades
Maravai Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Maravai Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Maravai Lifesciences Holdings backward and forwards among themselves. Maravai Lifesciences' institutional investor refers to the entity that pools money to purchase Maravai Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2024-06-30 | 3 M | Jennison Associates Llc | 2024-09-30 | 3 M | State Street Corp | 2024-06-30 | 2.8 M | Geode Capital Management, Llc | 2024-09-30 | 2.8 M | Point72 (difc) Ltd | 2024-09-30 | 2.7 M | Fmr Inc | 2024-09-30 | 2.5 M | Glenmede Trust Co Na | 2024-09-30 | 2.2 M | Alyeska Investment Group, L.p. | 2024-09-30 | 2.2 M | Bamco Inc | 2024-09-30 | 2.1 M | Gtcr Llc | 2024-09-30 | 20.2 M | 12 West Capital Management Lp | 2024-09-30 | 14 M |
Maravai Lifesciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Maravai Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Maravai Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Maravai Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Maravai Lifesciences Outstanding Bonds
Maravai Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Maravai Lifesciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Maravai bonds can be classified according to their maturity, which is the date when Maravai Lifesciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Maravai Lifesciences Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.